Emeis


Operational beat and deleveraging milestones tempered by cautious 2026 guidance

18/02/26 -"Emeis delivered a robust operational recovery in 2025, characterised by EBITDAR growth that exceeded management guidance and a further strengthened balance sheet, followed by the recent closing of ..."

Pages
56
Language
English
Published on
18/02/26
You may also be interested by these reports :
18/02/26
Emeis delivered a robust operational recovery in 2025, characterised by EBITDAR growth that exceeded management guidance and a further strengthened ...

16/02/26
The target price benefits from higher earnings expectations, along with a 20% premium added to the peer-based valuation. This reflects the firm’s ...

13/02/26
Dominant positioning for critical medical equipment (such as ventilators and heart-lung machines) in hospitals’ operating rooms, with two-thirds ...

12/02/26
CZM reported weak Q1 results, with challenges in both ophthalmology and microsurgery. Profitability declined significantly due to FX headwinds, an ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO